BUZZ-Aeterna Zentaris Inc: Data Safety Monitoring Board recommends continuing late-stage trial

Tue Apr 28, 2015 9:01am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Drug developer's U.S.-listed shares up 10.3 pct at $0.64 premarket

** Independent Data Safety Monitoring Board recommended Friday late-stage trial of company's experimental drug to treat type of cancer continue as planned

** Recommendation follows interim analysis of drug, zoptarelin doxorubicin, used to treat cancer arising from uterus lining

** Up to Monday's close, stock gained 82.3 pct this year